Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F2695 SR flexible-dose placebo-controlled phase 2 study in major depressive disorder
2006-002404-34Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing F2695 SR flexible dose with Placebo (2 arms). Primary endpoint: Change in MADRS total score from baseline to Day 70. Started Aug 2006; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-002404-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002404-34.